Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
12 studies found for:    LRRK2
Show Display Options
Download search resultsDownload the search results for:
LRRK2 (12 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Unknown  Clinical, Molecular and by Neuroimaging of LRRK2 Mutations
Condition: Parkinson's Disease
Intervention:
2 Terminated LRRK2 Mutation and Parkinson's Disease
Condition: Parkinson Disease
Interventions: Genetic: Healthy;   Genetic: PKD Patients
3 Active, not recruiting LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease
Condition: Parkinson's Disease
Intervention:
4 Recruiting Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation
Condition: Parkinson's Disease
Intervention: Other: colonoscopy or rectosigmoidoscopy
5 Terminated Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene Mutation
Condition: Parkinson Disease
Intervention:
6 Completed PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)
Condition: Parkinson Disease
Intervention:
7 Unknown  Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics
Condition: Parkinson Disease
Intervention:
8 Unknown  A Longitudinal Study in Parkinson's Disease (PD) Patients
Condition: Parkinson's Disease
Intervention: Other: neurological exam
9 Recruiting Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET
Conditions: Parkinson's Disease With LRRK2 Mutation;   Healthy Controls;   Parkinson's Disease Without LRRK2 Mutation
Interventions: Radiation: PET with the tracer 18F-DPA-714;   Radiation: PET with the tracer 11C-PE2I;   Other: MRI
10 Unknown  Parkin Mutations and Their Functional Consequences
Condition: Parkinson's Disease
Intervention:
11 Unknown  Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives
Condition: Parkinson Disease
Intervention:
12 Completed Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism
Condition: Parkinson's Disease
Intervention: Drug: 18F-DTBZ

Indicates status has not been verified in more than two years